Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease... see more

TSX:SZLS - Post Discussion

StageZero Life Sciences Ltd > Few Questions
View:
Post by NewToInvesting7 on Aug 17, 2021 3:19pm

Few Questions

First of all, I should say that I am disappointed at the significant drop in Covid testing revenues, especially since Stage added Rexall as a distributor of the test kits.  Would have thought it would be at least $1m. 

That said, I am still hopefully that the incoming members of the board, and the new CFO/COO will bring some much needed energy, strategy and goal execution for StageZero. 

What I want to see StageZero follow through on with frequent NRs releases, relate to the following:

1.  Completion of Care acquisition.
2.  Announcement of first AVRT/Aristotle revenues.
3.  Announcement of new partnerships that are currently not part of Care/HC.
4.  Announcement of ANY buy-out offers, regardless of whether the CEO thinks the offer is too low.
5.  Success stories of partnerships they converted from Covid testing to AVRT/Aristotle testing.

I can add more, like "is SEEK going to be an active partnership?", but sadly am too lazy to type right now.

https://seekacure.com/


Cheers!
Comment by Liked2Think on Aug 17, 2021 4:07pm
Yeah hopefully the company that runs at a break even has some good insight to the group but you wont see anything by Q3. Looks like no aristotle tests to date have been done.  New CFO starts at the end of Q3 time frame.  Q4 will not give the time for him to do anything really. If they were so confident covid revenue would return to Q1 levels why no update on how Q3 is doing so far ...more  
Comment by NewToInvesting7 on Aug 17, 2021 4:25pm
Q3 I expect more Covid revenues vs Q2, some of HC's Q3 revenues from "legacy" services, and some Aristotle/AVRT revenues.  Not expecting anyhing material, but hoping for total revenues to be $3m or so. Now, that's only revenues.  I expect an actual net loss, driven by one off integration costs, and not so much from operational expenses.  Igniring revaluation ...more  
Comment by TrippinAgain91 on Aug 17, 2021 4:58pm
This post has been removed in accordance with Community Policy
Comment by WalterYellow on Aug 17, 2021 6:34pm
This post has been removed in accordance with Community Policy
Comment by WalterYellow on Aug 17, 2021 6:36pm
This post has been removed in accordance with Community Policy
Comment by Kabron on Aug 17, 2021 10:45pm
Frustrating for sure... he did say there is a queue of patients for when they decide to start. The smart thing is to do is to issue a press release on when the testing has started and revenue should rocket from there. I think we were expecting covid revenues to drop but he did mention a few more covid revenue streams to expect. There are still millions of antivaxxers out there who would prefer to ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities